151 related articles for article (PubMed ID: 23615323)
1. Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda.
Mateen FJ; Kanters S; Kalyesubula R; Mukasa B; Kawuma E; Kengne AP; Mills EJ
J Hypertens; 2013 Jul; 31(7):1372-8; discussion 1378. PubMed ID: 23615323
[TBL] [Abstract][Full Text] [Related]
2. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study.
Reinsch N; Neuhaus K; Esser S; Potthoff A; Hower M; Mostardt S; Neumann A; Brockmeyer NH; Gelbrich G; Erbel R; Neumann T; ;
Eur J Prev Cardiol; 2012 Apr; 19(2):267-74. PubMed ID: 21450595
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.
Glass TR; Ungsedhapand C; Wolbers M; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC;
HIV Med; 2006 Sep; 7(6):404-10. PubMed ID: 16903986
[TBL] [Abstract][Full Text] [Related]
4. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital.
Julius H; Basu D; Ricci E; Wing J; Basu JK; Pocaterra D; Bonfanti P
Curr HIV Res; 2011 Jun; 9(4):247-52. PubMed ID: 21631427
[TBL] [Abstract][Full Text] [Related]
5. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
[TBL] [Abstract][Full Text] [Related]
6. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.
Mills EJ; Bakanda C; Birungi J; Chan K; Ford N; Cooper CL; Nachega JB; Dybul M; Hogg RS
Ann Intern Med; 2011 Aug; 155(4):209-16. PubMed ID: 21768555
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of baseline CD4(+) cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting.
Mills EJ; Bakanda C; Birungi J; Yaya S; Ford N;
AIDS; 2012 Jul; 26(11):1425-9. PubMed ID: 22526520
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
9. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy.
Baekken M; Os I; Sandvik L; Oektedalen O
J Hypertens; 2008 Nov; 26(11):2126-33. PubMed ID: 18854751
[TBL] [Abstract][Full Text] [Related]
10. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US.
Buchacz K; Baker RK; Palella FJ; Shaw L; Patel P; Lichtenstein KA; Chmiel JS; Vellozzi C; Debes R; Henry K; Overton ET; Bush TJ; Tedaldi E; Carpenter C; Mayer KH; Brooks JT;
Antivir Ther; 2013; 18(1):65-75. PubMed ID: 23111762
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study.
De Socio GV; Ricci E; Maggi P; Parruti G; Pucci G; Di Biagio A; Calza L; Orofino G; Carenzi L; Cecchini E; Madeddu G; Quirino T; Schillaci G;
Am J Hypertens; 2014 Feb; 27(2):222-8. PubMed ID: 24077828
[TBL] [Abstract][Full Text] [Related]
12. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
13. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
Bergersen BM; Sandvik L; Ellingsen I; Bruun JN
HIV Med; 2005 Jul; 6(4):260-7. PubMed ID: 16011531
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II.
McNicoll S; Latour Y; Rondeau C; Bouthillier D; Davignon J; Genest J
Can J Cardiol; 1995 Feb; 11(2):109-16. PubMed ID: 7866933
[TBL] [Abstract][Full Text] [Related]
16. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
Konopnicki D; Manigart Y; Gilles C; Barlow P; de Marchin J; Feoli F; Larsimont D; Delforge M; De Wit S; Clumeck N
J Infect Dis; 2013 Jun; 207(11):1723-9. PubMed ID: 23463709
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania.
Mullin S; Temu A; Kalluvya S; Grant A; Manji H
Trop Med Int Health; 2011 Oct; 16(10):1291-6. PubMed ID: 21707880
[TBL] [Abstract][Full Text] [Related]
18. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
[TBL] [Abstract][Full Text] [Related]
19. Premature age-related comorbidities among HIV-infected persons compared with the general population.
Guaraldi G; Orlando G; Zona S; Menozzi M; Carli F; Garlassi E; Berti A; Rossi E; Roverato A; Palella F
Clin Infect Dis; 2011 Dec; 53(11):1120-6. PubMed ID: 21998278
[TBL] [Abstract][Full Text] [Related]
20. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
